A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

Get up to date on the contemporary management of myelofibrosis and novel strategies with an expert commentary, downloadable slides, and an on-demand webcast from a live symposium.

Share

Program Content

Activities

Current Future MF
Selecting Initial Treatments and Future Directions in Myelofibrosis
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2023

Patterns First-Line MF Treatment
Recognizing Patterns of Suboptimal Response to First-Line MF Treatment
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2023

Activities

Master class in myelofibrosis care
Master Class in Personalized Myelofibrosis Care: New Evidence and Therapeutic Strategies to Improve Outcomes
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2023

Expires: December 17, 2024

Activities

Managing Myelofibrosis
Myelofibrosis: Where We Are and Where We Are Going
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2023

Activities

MF Key Presentations 2023
New Evidence and Novel Therapeutic Strategies in Myelofibrosis Care: Key Presentations at ASH 2023
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 29, 2023

Faculty

cover img faculity

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

cover img faculity

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from CTI BioPharma Corp., Geron Corporation, GlaxoSmithKline LLC, and Karyopharm Therapeutics Inc.

CTI BioPharma Corp

Geron Corporation

GlaxoSmithKline LLC

Karyopharm Therapeutics Inc.